<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486796</url>
  </required_header>
  <id_info>
    <org_study_id>MZ2014018</org_study_id>
    <nct_id>NCT02486796</nct_id>
  </id_info>
  <brief_title>Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer</brief_title>
  <official_title>A Comparison Study to Assess the Value of Naturopathic Medicine Given Immediately and Continuously or Delayed Until Cycle 3 in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christina Shannon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midwestern Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is examine the effect of the addition of naturopathic on immunologic and/or
      inflammatory parameters and/or quality of life in women receiving neoadjuvant chemotherapy
      for breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Operational barriers prevent critical specimen analyses from being performed.
  </why_stopped>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Actual">March 3, 2017</completion_date>
  <primary_completion_date type="Actual">March 3, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natural Killer Cell Activity by 51-chromium release assay (% activity released).</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject reported quality of life score</measure>
    <time_frame>4 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of C-reactive protein in serum (mg/L)</measure>
    <time_frame>4 month</time_frame>
    <description>The serum concentration of C-reactive protein will be measured by CLIA approved methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of circulating tumor cells in blood (cells per milliliter)</measure>
    <time_frame>4 month</time_frame>
    <description>The serum concentration of circulating tumor cells will be measured by CLIA approved methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedimentation rate of erythrocytes in blood (mm/hr)</measure>
    <time_frame>4 month</time_frame>
    <description>The erythrocyte sedimentation rate will be measured by CLIA approved methods.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Immediate and Continuous Dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Reishi mushroom extract</intervention_name>
    <description>Reishi mushroom preparation produced water-ethanol extraction.</description>
    <arm_group_label>Immediate and Continuous Dosing</arm_group_label>
    <arm_group_label>Delayed Dosing</arm_group_label>
    <other_name>Ganoderma lucidum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>Preparation of coenzyme Q10</description>
    <arm_group_label>Immediate and Continuous Dosing</arm_group_label>
    <arm_group_label>Delayed Dosing</arm_group_label>
    <other_name>Ubiquinone</other_name>
    <other_name>Ubidecarenone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Preparation of melatonin</description>
    <arm_group_label>Immediate and Continuous Dosing</arm_group_label>
    <arm_group_label>Delayed Dosing</arm_group_label>
    <other_name>N-acetyl-5-methoxy tryptamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          -  Biopsy proven diagnosis of invasive adenocarcinoma of the breast

          -  Recommendation for neoadjuvant chemotherapy.

          -  Left Ventricular Ejection Fraction (LVEF) assessment by multigated acquisition scan or
             echocardiogram within 3 months of entering study

          -  Blood counts:

          -  Absolute Neutrophil Count ≥1200 cells/mm^3

          -  Platelet count ≥100,000/mm^3

          -  Hemoglobin ≥10g/dL

          -  Serum creatinine ≤ Upper Limit of Normal (ULN) for the laboratory range

          -  Total bilirubin ≤ ULN for the laboratory range, unless the patient has an elevation
             &gt;ULN to 1.5 times the ULN resulting from Gilbert's disease or similar syndrome

          -  Alkaline phosphatase less than or equal to 2.5 x ULN; and

          -  Aspartate aminotransferase (AST) less than or equal to 1.5 x ULN for the laboratory
             range

          -  If skeletal pain present or alkaline phosphatase &gt;ULN (but less than or equal to 2.5x
             ULN), bone scan or Positron Emission Tomography (PET) scan must not demonstrate
             metastatic disease

          -  AST or alkaline phosphatase greater than ULN, no metastatic disease liver identified
             by CT, MRI or PET scan

          -  Able to swallow oral medication

          -  Willing to forego naturopathic treatment for the first 2 treatment cycles

          -  Willing to start and continue naturopathic interventions as prescribed

          -  Willing to forego the use of nutritional or botanical supplements during the study

        Exclusion Criteria:

          -  Stage 4 disease

          -  Present treatment with Warfarin.

          -  Synchronous bilateral invasive breast cancer

          -  Treatment including radiation, chemotherapy, and/or targeted therapy for the currently
             diagnosed breast cancer prior to entering study

          -  Any sex hormonal therapy e.g. birth control, ovarian hormone replacement therapy, etc.
             during participation in the study)

          -  Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other
             selective estrogen receptor modulators

          -  Prior history of breast cancer, including Ductal Carcinoma In Situ (subjects with a
             history of Lobular Carcinoma In Situ are eligible)

          -  Prior therapy with chemotherapy or targeted therapy agents for any malignancy

          -  Cardiac disease that would preclude the use of the certain drugs. This includes but is
             not confined to:

          -  Active cardiac disease

          -  Angina pectoris requiring treatment

          -  Ventricular arrhythmias except controlled benign premature ventricular contractions

          -  Conduction abnormality requiring a pacemaker

          -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled by
             medication

          -  Clinical significant valvular disease

          -  History of cardiac disease

          -  Myocardial infarction

          -  Congestive heart failure

          -  Cardiomyopathy

          -  Uncontrolled hypertension, (blood pressure above 150/90 mm/Hg on antihypertensive
             treatment)

          -  History or current symptomatic interstitial pneumonitis or pulmonary fibrosis

          -  Sensory/motor neuropathy ≥ grade 2

          -  Malabsorption syndrome, ulcerative colitis, resection the stomach or small bowel, or
             other disease significantly affecting gastrointestinal function

          -  Other non-malignant systemic disease precluding treatment with study regimens or
             required follow up

          -  Contraindication of corticosteroids

          -  Administration of an investigational agent within 30 days prior to entering study.

          -  Administration of therapeutic doses of the supplements being studied including
             maitake, melatonin and Coenzyme Q10 in the previous 30 days.

          -  Administration of therapeutic doses of immune modulating botanicals in the previous 30
             days.

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Shannon, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwestern Regional Medical Center, Inc.</affiliation>
  </overall_official>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Midwestern Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Christina Shannon</investigator_full_name>
    <investigator_title>Clinical Director Naturopathic Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

